Inhibitory Concentration 50
"Inhibitory Concentration 50" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
| Descriptor ID |
D020128
|
| MeSH Number(s) |
E05.940.350 G07.690.936.563
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Inhibitory Concentration 50".
Below are MeSH descriptors whose meaning is more specific than "Inhibitory Concentration 50".
This graph shows the total number of publications written about "Inhibitory Concentration 50" by people in this website by year, and whether "Inhibitory Concentration 50" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 5 | 5 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 37 | 37 |
| 2018 | 0 | 31 | 31 |
| 2019 | 0 | 13 | 13 |
| 2020 | 0 | 14 | 14 |
| 2021 | 0 | 13 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Inhibitory Concentration 50" by people in Profiles.
-
Drug Repurposing for the SARS-CoV-2 Papain-Like Protease. ChemMedChem. 2022 01 05; 17(1):e202100455.
-
Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. Int J Mol Sci. 2021 Aug 22; 22(16).
-
Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. Antiviral Res. 2021 09; 193:105142.
-
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.
-
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. Biochem J. 2021 07 16; 478(13):2517-2531.
-
Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. PLoS One. 2021; 16(7):e0253364.
-
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors. Bioorg Med Chem Lett. 2021 09 15; 48:128263.
-
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Cell Chem Biol. 2021 12 16; 28(12):1795-1806.e5.
-
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia. PLoS One. 2021; 16(6):e0252302.
-
Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors. Eur J Med Chem. 2021 Nov 05; 223:113622.